TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $767,579 | -19.0% | 85,859 | +39.2% | 0.00% | – |
| Q2 2023 | $947,466 | -90.2% | 61,684 | -85.7% | 0.00% | – |
| Q1 2023 | $9,704,884 | +156.1% | 431,520 | +139.5% | 0.00% | – |
| Q4 2022 | $3,788,912 | -63.3% | 180,167 | -57.0% | 0.00% | -100.0% |
| Q3 2022 | $10,322,000 | -2.9% | 418,905 | -4.5% | 0.00% | 0.0% |
| Q2 2022 | $10,632,000 | -1.3% | 438,814 | +4.9% | 0.00% | 0.0% |
| Q1 2022 | $10,777,000 | -6.9% | 418,184 | +12.1% | 0.00% | 0.0% |
| Q4 2021 | $11,576,000 | +28.0% | 372,928 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $9,044,000 | +4952.5% | 372,928 | +2932.2% | 0.00% | – |
| Q2 2021 | $179,000 | -98.8% | 12,299 | -97.9% | 0.00% | -100.0% |
| Q1 2021 | $14,972,000 | -17.7% | 599,599 | -10.2% | 0.00% | -50.0% |
| Q4 2020 | $18,193,000 | – | 667,499 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |